anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Oncolytic viruses offer an in situ vaccination approach to activate tumor-specific T cell responses. However, the upregulation of PD-L1 expression on tumor cells and immune cells leads to tumor resistance to oncolytic immunotherapy. Herein, we generate an engineered oncolytic virus that coexpresses a PD-L1 inhibitor and GM-CSF. This oncolytic virus is capable of secreting the PD-L1 inhibitor that systemically binds and inhibits PD-L1 on tumor cells and immune cells. The intratumoral injection with the oncolytic virus overcomes PD-L1-mediated immunosuppression during both the priming and effector phases, provokes systemic T cell responses against dominant and subdominant neoantigen epitopes derived from mutations, and leads to an effective rejection of both virus-injected and distant tumors. This engineered oncolytic virus allows for activation of tumor neoantigen-specific T cell responses, providing a potent, individual tumor-specific oncolytic immunotherapy for cancer patients, especially those resistant to PD-1/PD-L1 blockade therapy.
The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
Module adaptable to communicate with a suitable handheld devices or PDAs. Suitable devices include, but are not limited to, the Apple iPhone® or iPod®, Research in Motion Blackberry® smart phones, Motorola Droid smart phones, and Palm Pre smart phones. The module can be used without adding to the cost of the handheld device. This allows direct reimbursement for the replaceable meter module portion if payers choose to limit coverage for the full system, as well as the possibility of reimbursement for the entire system including the handheld device. Other solutions build the cost into the phone, which must be replaced to upgrade or replace the glucose function. Moreover, information from the glucose meter reading can be communicated from the PDA to a remote station for reporting the results. With an iPod- like approach, this could be accomplished without the need for a cellular signal or carrier, as long as a WiFi internet connection is available anywhere in the world.
PURPOSE:A carcinostatic agent comprising a substance obtained by bonding apoprotein of high polymer polypeptide carcinostatic agent to chromophore of high polymer polypeptide carcinostatic agent in a specific ratio as an active ingredient. CONSTITUTION:A fixed amount of apoprotein is dissolved in water. On the other hand, a fixed amount of chromophore is dissolved in a water-miscible organic solvent (e.g., methanol). Then, both the solutions are blended in such a way that they are subjected to hydrogen bond and/or hydrophobic bond in a ratio of 1 apoprotein molecule to >=11 chromophore molecules, the organic solvent is removed and the resultant substance is lyophilized. The prepared lyophilized powder is redissolved in water. If an insoluble substance exists, it is removed by centrifugation and a water-soluble fraction is isolated and purified to give a bond substance. A carcinostatic agent having improved toxicity and carcinostatic spectrum, containing it as an active ingredient, is obtained.
Body image distortion is an alteration in the perception of the body that can have repercussions on health. This study aims to estimate the prevalence of body image accuracy and distortion among women participating in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) living in Bahia State, Brazil, and to investigate associations with socioeconomic characteristics, lifestyle, and gynecological care seeking. A total of 609 women aged 50 to 69 years participated in the study, who answered face-to-face questionnaires from 2012 to 2014. The Stunkard silhouette scale was used to investigate accurate or distorted perception for more or less weight. The relative risk ratio (RR) was calculated by multinomial logistic regression using Stata 13. Most participants have an accurate perception of their own bodies (53.7%). Among those with distorted perception, there is a tendency to distort towards less weight (38.1%). In the multinomial regression analysis, the variables race/skin color and education remained associated with the distortion towards underweight. The race/skin color variable was positively associated with the distortion towards underweight among Mixed-race women (RR = 1.89; 95%CI: 1.13-3.16) and black (RR = 2.10; 95%CI: 1.25-3.55), while the education variable among those with up to high school education (RR = 1.65; 95%CI: 1.18-2.33). There were no associations with the other variables or with distortion for more weight. The results contribute to explaining the relationships between body image perception and socioeconomic factors, revealing that women of different races/skin colors and varying educational levels are influenced in different ways by social discourses, impacting the perception of their body image.
This is a randomized (individuals will be assigned by chance to study treatments), open-label (identity of assigned study drug will be known), 4-way crossover study to compare the effect of food and two fasting regimens on the pharmacokinetics of PCI-32765 in healthy adults. There will be approximately 52 (at least 25% women) participants (11 in each sequence in the 4-way crossover and 8 in an optional cohort). A screening phase will be followed by an open-label treatment phase consisting of 4 single-dose treatment periods of 420 mg PCI-32765 administered with or without food. Doses in successive open-label treatment periods will be separated by a washout period of 7 days. Participants will be confined to the study center from Day -1 of each treatment period (at least 10 hours before each study drug administration) until completion of the 72 hour pharmacokinetic blood sample collection on Day 4 of Period 4. Blood samples for pharmacokinetic analysis of PCI-32765 and metabolite PCI-45227 will be collected before dosing and over 72 hours after dosing in each treatment period. A follow-up visit approximately 10 days after the last dose will be made to measure lymphocyte count and to capture any additional adverse events. After completion of the 4-way crossover portion of the study, and in absence of significant safety observations at the 420 mg PCI-32765 dose, an additional separate cohort of 8 participants may be enrolled to participate in one treatment period and receive a dose of 840 mg in combination with a high-fat breakfast. Safety will be assessed throughout the study. The total study duration is a maximum of 85 days.
Although pregnancy is a natural process, the change in physiological and psychosocial balance and the differentiation of roles in life require bio-psychosocial adaptation for the pregnant woman and her environment. In addition to strengthening the uterine and perineal muscles and supporting the spine, yoga is effective in dealing with common problems of pregnancy such as poor blood circulation, blood pressure fluctuations, excessive weight gain, fatigue, edema and urinary problems. The study will investigate the effects of pregnancy yoga on perceived stress, quality of sexual life and sleep level. A total of 100 pregnant women are planned to be included in the study. Data will be collected with the "Personal Information Form", "Perceived Stress Scale" and "Sexual Quality of Life Questionnaire-Female". Yoga will be applied to the experimental group for a total of 12 sessions, two sessions per week (90 minutes) for six weeks. The research predicts that yoga will reduce the stress perceived by pregnant women, increase the quality of sexual life and positively affect sleep patterns.
Techniques for generating recommendations using machine learning with respect to semantic concepts defined in a knowledge graph. A hair profile is determined for a user based on inputs related to the user. Determining the hair profile includes extracting attributes of the user from the inputs using natural language processing, computer vision, or both, and identifying respective nodes for the extracted attributes in the knowledge graph. The knowledge graph is created via machine learning using population data including hair-related data in order to identify relationships between semantic concepts represented by nodes of the knowledge graph. The nodes include discrete properties such as individual hair attributes, ingredients of products, or otherwise discrete characteristics of factors that may affect a user's hair or related health conditions. A generalized recommendation is generated based on the hair profile. A personalized recommendation may be generated based on the generalized recommendation and progress logged by the user.
Tibialis anterior tendon (TAT) transfer to the lateral cuneiform is commonly utilized to treat dynamic supination for relapsed clubfoot deformity. Traditional suture button fixation (SBF) may lead to skin necrosis at the button/skin interface. While interference screw fixation (ISF) would mitigate this concern, this fixation method has not been investigated in clubfoot patients. This study aims to investigate the performance of ISF versus SBF for TAT transfer in a cadaveric model. Ten matched pairs of cadaveric feet were obtained. One of each matched specimen underwent TAT transfer to the lateral cuneiform using ISF and the other underwent TAT transfer using SBF. For each ISF specimen, the tension of the transferred TAT required to bring the ankle to neutral was measured. This tension was then applied to both matched specimens using an MTS machine. Tension dissipation was measured after a 20-minute interval. In specimens with SBF, a load cell was positioned between the plantar skin and suture button to determine plantar skin pressure at the time of initial tension application. Average tension necessary to achieve neutral dorsiflexion was 49.4 N. Average tension dissipation after 20 min was significantly less in the IFS group (20 N versus 23.6 N, P  = 0.02). No fixation failures occurred in either group. Average plantar foot skin pressure was 196.5 mmHg at initial tension application, exceeding thresholds for tissue ischemia. ISF allows for tendon tensioning at forces beyond those expected to result in skin necrosis with SBF with less dissipation of tension over time.
Participants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, the subject will perform a 40-minute walk on a flat surface, preceded by a warm-up phase and followed by a 10 minute warm-down phase each. Subjects will walk back and forth over a distance of approximately 30 metres using their walking aid.
Complete and consistent binding to IL-2Rα in adults is maintained as long as serum Simulect levels exceed 0.2 mcg/mL. As concentrations fall below this threshold, the IL-2Rα sites are no longer fully bound and the number of T-cells expressing unbound IL-2Rα returns to pretherapy values within 1-2 weeks. The relationship between serum concentration and receptor saturation was assessed in 13 pediatric patients and was similar to that characterized in adult renal transplantation patients. In vitro studies using human tissues indicate that Simulect binds only to lymphocytes.

The duration of clinically relevant IL-2 receptor blockade after the recommended course of Simulect is not known. When basiliximab was added to a regimen of cyclosporine, USP (MODIFIED) and corticosteroids in adult patients, the duration of IL-2Rα saturation was 36 ± 14 days (mean ± SD), similar to that observed in pediatric patients (36 ± 14 days) (see DOSAGE AND ADMINISTRATION). When basiliximab was added to a triple therapy regimen consisting of cyclosporine, USP (MODIFIED), corticosteroids, and azathioprine in adults, the duration was 50 ± 20 days and when added to cyclosporine, USP (MODIFIED), corticosteroids, and mycophenolate mofetil in adults, the duration was 59 ± 17 days (see PRECAUTIONS, Drug Interactions). No significant changes to circulating lymphocyte numbers or cell phenotypes were observed by flow cytometry.
Compositions comprising the extract of Enteromorpha sp. are provided to inhibit growth of fungi, especially Malassezia sp. causing dandruff without side effects and tolerance, so that the compositions are useful for improvement, prevention and treatment of dandruff and seborrheic dermatitis. An antifungal composition comprises the extract of Enteromorpha sp. selected from Enteromorpha linza, Enteromorpha intestinalis, Enteromorpha compressa, Enteromorpha prolifera and Enteromorpha clathrata, which is prepared by extracting Enteromorpha sp. with a solvent selected from ether, chloroform, benzene, hexane and dichloromethane, wherein the composition shows antifungal effects on Malassezia sp. selected from Malassezia furfur, Malassezia restricta, Malassezia obtusa, Malassezia globosa, Malassezia slooffiae, Malassezia sympodialis and Malassezia pachydermatis. Further, the antifungal composition is used as a composition for preventing or treating dandruff and dermatitis.
A light-coloured oil with a substantially reduced content of peroxides and other harmful substances is obtained from the oil of marine animals by adding an antioxidant and electrolytically reducing it in the presence of a neutral or alkaline electrolyte. The highly unsaturated fatty acid constituents remain undegraded and the purified and stabilized oil is used to prepare a medicinal agent for the treatment of hyper-cholesterolemia in conventional manner.  The oils of sardine, herring, bonito, whale, mackerel and saury pike may be used as well as oil of the internal organs of cuttlefish and residual oils obtained in the production of vitamin oils such as liver oils of pollack, cod, shark, tunny and whale. The electrolyte may be an alkali metal hydroxide or carbonate, for example sodium hydroxide, a salt of an organic acid, e.g. sodium acetate, or sodium chloride or sulphate.  Reduction may be carried out in the presence of aluminium magnesium or zinc powder. Suitable anti-oxidants are N.D.G.A. (nordihydroguaiaretic acid), propyl gallate, B.H.A., B.H.T. (respectively butylated hydroxy - anisole, -toluene) and a -tocopherol.ALSO:Oil of fish or marine animals is electrolytically reduced in the presence of a neutral or alkaline electrolyte solution preferably containing aluminium, magnesium or zinc powder.  An antioxidant such as N.D.G.A. (nordihydroguiaretic acid), propyl gallate, B.H.A., B.H.T. (butylated hydroxy-anisole, -toluene respectively), or a -tocopherol is added to the oil before electrolysis.  The electrolyte may be an alkali metal, e.g. sodium hydroxide, an alkali metal carbonate, sodium chloride or sulphate, or a salt of an organic acid, e.g. sodium acetate, and the cathode is preferably zinc, lead, tin or cadmium.  A diaphragm cell is preferred.ALSO:A medicinal agent for the treatment of hypercholesterolemia comprises purified and stabilized oil of fish or marine animals together with vitamin B6 palmitate, inositol, a -tocopherol and an emulsifier.  The oil is stabilized with an antioxidant which may be N.D.G.A (nordihydrognaiaretic acid), propyl gallate, B.H.A (butylated hydroxyanisole), B.H.T. (butylated hydroxytoluene or a -tocopherol and then purified by electrolytic reduction in the presence of neutral or alkaline electrolyte.  The medicinal agent may be prepared in the form of capsule, oily preparation, emulsion or gelatin-coated granite.  For example gelatin-coated granules may be made by dispersing the purified oil, vitamin B6 palmitate &c. in gelatin solution, injecting the dispersion into a mass of water-repellent substance such as starch esters, drying the mixture and sieving the powder, or suspending the dispersion in mineral or vegetable oil, coagulating it by cooling, filtering, washing and drying.
There has been no experience with overdosage of SPRIX. In controlled overdosage studies with IM ketorolac injection, daily doses of 360 mg given for five days (approximately 3 times the maximum daily dose of SPRIX) caused abdominal pain and peptic ulcers, which healed after discontinuation of dosing. Single overdoses of ketorolac tromethamine have been variously associated with abdominal pain, nausea, vomiting, hyperventilation, peptic ulcers and/or erosive gastritis, and renal dysfunction. 

Symptoms and Signs

Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur, but are rare. 

Treatment

Manage patients using symptomatic and supportive care following an NSAID overdose. There are no specific antidotes. Activated charcoal (60 g to 100 g in adults, 1 g/kg to 2 g/kg in children) may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large oral overdose (5 to 10 times the usual dose). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.
The present invention pertains to oil-in-water emulsion compositions having hydrophobic materials stably dispersed therein and methods for making such. The preferred method of making the emulsion compositions the formation of two O/W emulsions. A first O/W emulsion is for wetting or otherwise pre-treating the hydrophobic components. Thereafter, the first emulsion is added to a second O/W emulsion after the second emulsion has been formed. Both emulsions use a ternary surfactant blend of cationic, anionic and bridging surfactants, making the finished product a double or 'binary-CAN' emulsion system. Generally, the system has a bi-modal oil droplet distribution.
<P>PROBLEM TO BE SOLVED: To provide a hair-strengthening agent that gives sufficient hair-strengthening effects with good persistency of the effects to a damaged hair, a hair cosmetic composition and a hair-strengthening method using these.  <P>SOLUTION: The hair-strengthening agent comprises ectoine as an effective ingredient. The hair cosmetic composition comprises the hair-strengthening agent. The hair-strengthening method comprises applying the composition to the hair. More preferably, the hair cosmetic composition further comprises a nitrogen-containing polymer such as a cationic cellulose derivative, a dimethyldiallyl quaternary ammonium salt derivative, an amino-modified silicone, a polypeptide or the like.  <P>COPYRIGHT: (C)2009,JPO&INPIT
1,163,044. Treatment of acne. STIEFEL LABORATORIES Inc. 6 Feb., 1967 [30 March, 1966], No. 5525/67. Heading A5B. A therapeutic composition for the treatment of acne, which composition is stable in storage without the addition of a stabilizer thereto, comprises a uniform dispersion of crystalline benzoyl peroxide in a water- and organicemollient-containing fluid medium, the organic emollient constituents comprising organic compounds that are inert, nonpolar and non- ionic with respect to the other constituents of the composition and that have a boiling point higher than water, the composition containing from 1 to 25% by weight benzoyl peroxide, from 2 to 25% by weight of organic emollient and from 50 to 90% by weight water. Suitable organic emollients are aliphatic alcohols having 4 to 20 carbon atoms; glycols having from 2 to 3 carbon atoms and polymers of these glycols; fatty acids having 12 to 20 carbon atoms and esters thereof. Specific emollients mentioned are butyl, isobutyl, amyl, isoamyl, hexyl and isohexyl alcohols; ethylene, diethylene, polyethylene and propylene glycols; lauric, . myristic, palmitic and stearic acids; ethly and isopropyl laurate; ethyl, n-propyl and isopropyl myristate; ethyl, isopropyl and methyl palmitate; methyl, ethyl, isopropyl, buytl, isobutyl, amyl and isoamyl stearate; butyl, propyl and isopropyl oleate. Sulphur may be present as an additional active substance. The composition may also contain at least one emulsifier for the aqueous and non- aqueous phases of the fluid medium.
BACKGROUND: Among people living with frailty, adherence to a healthy lifestyle may be a low-cost and effective strategy to decrease frailty-induced health risks across different social environments.
METHODS: We included 15 594 frail participants at baseline from the UK Biobank study. We used four lifestyle factors to create a composite healthy lifestyle score and 17 social factors to construct a polysocial score. We classified the lifestyle score into two levels (unhealthy and healthy) and the polysocial score into three levels (low, intermediate and high). We used Cox regression to determine the association of each lifestyle factor and lifestyle score with all-cause mortality, respectively. We also examined the associations across polysocial score categories. We evaluated the joint association of the lifestyle score and the categorical polysocial score with all-cause mortality.
RESULTS: During up to 14.41 follow-up years, we documented 3098 all-cause deaths. After multivariable adjustment, we found a significant association between not smoking and adequate physical activity with all-cause mortality across polysocial score categories, respectively. We also found a significant association between a healthy diet and all-cause mortality among frail participants living in an intermediate social environment. A healthy lifestyle was associated with a lower all-cause mortality risk across polysocial score categories, especially among those with a low polysocial score.
CONCLUSIONS: Adherence to a healthy lifestyle, particularly not smoking, adequate physical activity and a healthy diet, may provide a feasible solution to decreasing mortality risk among frail adults across different social environments, especially for those in the socially disadvantaged group.
Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor. Patients continue on this regimen, watching for tumor growth, up to 2 years on study or until rate or extent of growth leads to a shared decision to initiate treatment, whichever comes first.